A phase II trial of an alternative schedule of palbociclib and embedded serum TK1 analysis

Abstract Palbociclib 3-weeks-on/1-week-off, combined with hormonal therapy, is approved for hormone receptor positive (HR+)/HER2-negative (HER2−) advanced/metastatic breast cancer (MBC). Neutropenia is the most frequent adverse event (AE). We aim to determine whether an alternative 5-days-on/2-days-...

Full description

Bibliographic Details

Published in:	npj Breast Cancer
Main Authors:	Jairam Krishnamurthy, Jingqin Luo, Rama Suresh, Foluso Ademuyiwa, Caron Rigden, Timothy Rearden, Katherine Clifton, Katherine Weilbaecher, Ashley Frith, Anna Roshal, Pavan K. Tandra, Mathew Cherian, Tracy Summa, Brittney Haas, Shana Thomas, Leonel Hernandez-Aya, Mattias Bergqvist, Lindsey Peterson, Cynthia X. Ma
Format:	Article
Language:	English
Published:	Nature Portfolio 2022-03-01
Online Access:	https://doi.org/10.1038/s41523-022-00399-w